Medicine:Hepatosplenic T-cell lymphoma
| Hepatosplenic T-cell lymphoma | |
|---|---|
| Other names | hepatosplenic γδ T-cell lymphoma[1] |
| Specialty | Hematology and oncology |
Hepatosplenic T-cell lymphoma is a rare form of lymphoma that is generally incurable, except in the case of an allogeneic stem cell transplant.[2][3] It is a systemic neoplasm comprising medium-sized cytotoxic T-cells that show significant sinusoidal infiltration in the liver, spleen, and bone marrow.[1]
Signs and symptoms
The typical clinical finding in a patient with hepatosplenic T-cell lymphoma is hepatosplenomegaly.[4]
The spleen and liver are always involved, and bone marrow involvement is common. Nodal involvement is exceedingly rare.[1][5]
Cause
The cell of origin for this disease is an immature cytotoxic T-cell clonally expressing the γδ T-cell receptor. The disease is seen more often in immunosuppressed recipients of solid organ transplants, an association that has led to the hypothesis that long-term immune stimulation in the setting of immunosuppression is the causative agent.[citation needed]
Cases of hepatosplenic T-cell lymphoma have been reported in patients treated with the immunosuppressants azathioprine, infliximab, and adalimumab. The majority of cases occurred in patients with inflammatory bowel disease. Adolescents and young adult males were most frequently affected. They presented with a very aggressive disease course, and all but one died. The Food and Drug Administration required changes to the drugs' labeling to inform users and clinicians of the risk.[6][7][8]
Diagnosis
The neoplastic cells in hepatosplenic T-cell lymphoma show a monotonous appearance, with a small amount of cytoplasm and inconspicuous nucleoli.[5]
Laboratory findings
The constellation of thrombocytopenia, anemia, and leukopenia is common in patients with hepatosplenic T-cell lymphoma.[9]
Spleen and liver
The disease shows a distinct sinusoidal pattern of infiltration which spares the splenic white pulp and hepatic portal triads.[1]
Bone marrow
While the bone marrow is commonly involved, the detection of the neoplastic infiltrate may be difficult due to a diffuse, interstitial pattern. Immunohistochemistry can aid in diagnosis.[1]
Peripheral blood
Cells of a similar morphology observed in solid organs are observed in peripheral blood.[1]
Immunophenotype
The immunophenotype for hepatosplenic T-cell lymphoma is a post-thymic, immature T-cell.[1][5]
| Status | Antigens |
| Positive | CD3, TCRδ1, TIA-1 |
| Negative | CD4, CD5, CD8 |
Genetic findings
Clonal rearrangement of the γ gene of the T-cell receptor is the hallmark of hepatosplenic T-cell lymphoma. A few cases have shown rearrangement of the T-cell receptor β gene.[1] Isochromosome 7q has been observed in all cases described so far, sometimes in conjunction with other chromosomal abnormalities such as trisomy 8.[10]
Treatment
The CHOP chemotherapy regimen frequently induces remission but has proven weak compared to treatments that integrate cytarabine, with Hyper-CVAD being particularly effective. When treated solely with chemotherapy, most patients relapse and die within two years. Treatment solely with doxorubicin can make the disease worse.[citation needed]
Allogeneic bone marrow transplantation has been shown to induce remission for more than five years and possibly cure hepatosplenic lymphoma. [2] [citation needed] Autologous bone marrow transplantation is currently being investigated.[citation needed]
Epidemiology
Hepatosplenic lymphoma is rare, comprising less than 5% of all lymphoma cases, and is most common in young adults and adolescents. A distinct male gender preference has been described.[5]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Elaine Sarkin Jaffe, Nancy Lee Harris, World Health Organization, International Agency for Research on Cancer, Harald Stein, J.W. Vardiman (2001). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. 3. Lyon: IARC Press. ISBN 92-832-2411-6. https://books.google.com/books?id=XSKqcy7TUZUC.
- ↑ 2.0 2.1 Rashidi, A.; Cashen, A. F. (2015). "Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma". Blood Cancer Journal 5 (6): e318. doi:10.1038/bcj.2015.43. PMID 26047388.
- ↑ "Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease". J. Pediatr. Gastroenterol. Nutr. 44 (2): 265–7. February 2007. doi:10.1097/MPG.0b013e31802f6424. PMID 17255842.
- ↑ "Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta". Blood 75 (11): 2213–9. June 1990. doi:10.1182/blood.V75.11.2213.2213. PMID 2140703. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=2140703.
- ↑ 5.0 5.1 5.2 5.3 "Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin". Blood 88 (11): 4265–74. December 1996. doi:10.1182/blood.V88.11.4265.4265. PMID 8943863. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=8943863.
- ↑ FDA Warning concerning azathioprine and Hepatosplenic T-cell lymphoma https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258794.htm
- ↑ "Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen". Am. J. Clin. Pathol. 102 (3): 310–5. September 1994. doi:10.1093/ajcp/102.3.310. PMID 8085554.
- ↑ "Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas". Am. J. Surg. Pathol. 25 (3): 285–96. March 2001. doi:10.1097/00000478-200103000-00002. PMID 11224598.
- ↑ Alsohaibani, Fahad I.; Abdulla, Maheeba A.; Fagih, Mousa M. (2011). "Hepatosplenic T-Cell Lymphoma". Indian Journal of Hematology and Blood Transfusion 27 (1): 39–42. doi:10.1007/s12288-010-0051-1. ISSN 0971-4502. PMID 22379294.
- ↑ "Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma". Leukemia 11 (8): 1367–72. August 1997. doi:10.1038/sj.leu.2400742. PMID 9264394.
External links
| Classification | |
|---|---|
| External resources |
 |  |
